PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2018

Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.

Rat / Chemical/toxin

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 29776437 ↗2018Reported benefit

Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.

RatChemical/toxinSprague-DawleyMalen = n = 8 per group (animal arm); parallel randomised clinical…Oral gavage10 mg/kg or 20 mg/kg of each drugThree days before contrast medium injection and again 4 h after

Model: Contrast medium-induced acute kidney injury: 72 h water deprivation, furosemide 10 mg/kg intramuscularly, then 20 min later iohexol (350 mg I/mL) 10 mL/kg intravenously via tail vein over 5 min

Coenzyme Q10 plus trimetazidine dose-dependently lowered blood urea nitrogen and creatinine, reduced lipid peroxidation, raised glutathione, superoxide dismutase and catalase, and reduced tubular necrosis scores relative to contrast medium alone.

Extraction: extract · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.